Literature DB >> 31584946

A systematic review and evaluation of Zika virus forecasting and prediction research during a public health emergency of international concern.

Pei-Ying Kobres1, Jean-Paul Chretien2, Michael A Johansson3, Jeffrey J Morgan4, Pai-Yei Whung5, Harshini Mukundan6, Sara Y Del Valle6, Brett M Forshey7, Talia M Quandelacy3,8, Matthew Biggerstaff9, Cecile Viboud10, Simon Pollett11,12,13.   

Abstract

INTRODUCTION: Epidemic forecasting and prediction tools have the potential to provide actionable information in the midst of emerging epidemics. While numerous predictive studies were published during the 2016-2017 Zika Virus (ZIKV) pandemic, it remains unknown how timely, reproducible, and actionable the information produced by these studies was.
METHODS: To improve the functional use of mathematical modeling in support of future infectious disease outbreaks, we conducted a systematic review of all ZIKV prediction studies published during the recent ZIKV pandemic using the PRISMA guidelines. Using MEDLINE, EMBASE, and grey literature review, we identified studies that forecasted, predicted, or simulated ecological or epidemiological phenomena related to the Zika pandemic that were published as of March 01, 2017. Eligible studies underwent evaluation of objectives, data sources, methods, timeliness, reproducibility, accessibility, and clarity by independent reviewers.
RESULTS: 2034 studies were identified, of which n = 73 met the eligibility criteria. Spatial spread, R0 (basic reproductive number), and epidemic dynamics were most commonly predicted, with few studies predicting Guillain-Barré Syndrome burden (4%), sexual transmission risk (4%), and intervention impact (4%). Most studies specifically examined populations in the Americas (52%), with few African-specific studies (4%). Case count (67%), vector (41%), and demographic data (37%) were the most common data sources. Real-time internet data and pathogen genomic information were used in 7% and 0% of studies, respectively, and social science and behavioral data were typically absent in modeling efforts. Deterministic models were favored over stochastic approaches. Forty percent of studies made model data entirely available, 29% provided all relevant model code, 43% presented uncertainty in all predictions, and 54% provided sufficient methodological detail to allow complete reproducibility. Fifty-one percent of predictions were published after the epidemic peak in the Americas. While the use of preprints improved the accessibility of ZIKV predictions by a median of 119 days sooner than journal publication dates, they were used in only 30% of studies.
CONCLUSIONS: Many ZIKV predictions were published during the 2016-2017 pandemic. The accessibility, reproducibility, timeliness, and incorporation of uncertainty in these published predictions varied and indicates there is substantial room for improvement. To enhance the utility of analytical tools for outbreak response it is essential to improve the sharing of model data, code, and preprints for future outbreaks, epidemics, and pandemics.

Entities:  

Year:  2019        PMID: 31584946      PMCID: PMC6805005          DOI: 10.1371/journal.pntd.0007451

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


Introduction

Zika virus (ZIKV) is a positive-sense RNA flavivirus primarily transmitted through the Aedes aegypti mosquito [1-3]. While the majority of ZIKV infections are asymptomatic or present as a self-limiting febrile illness, strong evidence links ZIKV infection with microcephaly and a range of other birth defects, including limb deformity and retinopathy [4, 5]. ZIKV is also associated with Guillian-Barré syndrome, and a spectrum of other neurological disorders including meningoencephalitis and acute myelitis [6-9]. ZIKV was discovered in Uganda in a febrile non-human primate in 1947 [10], and the first human case was detected in Nigeria in 1953 [11]. ZIKV outbreaks were detected in Southeast Asia and the Pacific Islands in the early 21st century [12-16] followed by wide spread epidemics in the Americas from late 2014 onward, with a cumulative count of 583,144 suspected and 223,336 laboratory-confirmed Zika cases reported across 49 countries and territories by the end of 2017 [17, 18]. The Director-General of the World Health Organization declared the ZIKV pandemic a public health emergency of international concern (PHEIC) on February 1, 2016 [19]. The urgency for immediate coordinated global response was further accelerated by the Olympic and Paralympic games set to take place in Rio De Janeiro, Brazil during August 2016 [20]. As public health and medical research efforts for Zika increased across the Americas, scientists developed mathematical models to anticipate further outbreak spread, evaluate possible control measures, and gain insight into outbreak dynamics. These models used a range of data sources including case counts, relative vector abundance and distribution, population age structure, human mobility, climate information, viral sequence and serological data, and internet ‘big data’ streams. A range of statistical and mathematical models predicted the spread and other epidemic dynamics of ZIKV, as well as the burden of its complications [21-26]. While the WHO PHEIC status was lifted in November 2016 and the neotropical Zika pandemic has waned, the forecasting activities during the pandemic have not been systematically examined, particularly whether the studies were published in a manner and time-frame that was actionable during the Zika pandemic [27]. Such an exercise is critical, not only due to the ongoing risk of Zika globally [28], but also to inform modeling efforts for future major epidemics. We therefore undertook a systematic review to identify all published ZIKV prediction and forecasting studies during a time period which encompassed the PHEIC period and the peak and waning phase of the epidemic in the Americas. The first aim of this systematic review was to identify all published models that predicted, forecasted, or simulated any ecological or epidemiological phenomenon about the Zika pandemic and describe the predicted phenomena, the range of data sources used, and the modeling methods employed. This first aim sought to characterize the methods and data employed to answer key questions during the epidemic and to identify potentially underutilized data or methods. The second aim was to evaluate key scientific characteristics of these studies, including (i) accessibility and timeliness of the publication, (ii) reproducibility of the methods and access to the statistical code and data, and (iii) clarity of the presentation of the prediction results, including uncertainty in prediction estimates. The third aim was to describe the funding structure and major contributing sectors, such as government, industry, non-governmental organizations, or academia, behind these publications.

Methods

The PRISMA and Cochrane systematic review guidelines were adopted [29]. A panel of 12 investigators developed the systematic review protocol including the eligibility criteria and the data abstraction tool. No formal protocol was published for this systematic review.

Literature search strategy

We conducted a literature review using EMBASE and MEDLINE (PubMed) to identify all potentially eligible studies, which predicted or forecasted phenomena of the ZIKV pandemic. In MEDLINE we performed a highly sensitive search solely using the term “Zika.” A complementary search in EMBASE used a more specific ontology: “Zika AND (forecasting OR prediction OR model OR modeling OR modelling OR risk OR estimating OR dynamics) NOT mouse.” Both database searches were limited to articles published as of March 1, 2017, and the MEDLINE searches were restricted to publications released between February 1, 2016 and March 1, 2017. We used this end date to capture those models published during a time-frame of major operational relevance (that is, during the early, peak, and waning phase of the Americas epidemic). We complemented these database search results with ‘grey literature,’ including hand-searched bibliographies of major Zika epidemiological review articles [17, 30, 31] and contacting experts in the field of Zika modeling to identify any studies which may have been missed by the above search strategies.

Screening and eligibility determination

Using a two-reviewer system (with consensus for disagreements and conferral with a 3rd party adjudicator if a consensus was unable to be reached), all articles identified through the above literature search were screened by reviewing the title and abstract to remove all articles that clearly did not meet the eligibility criteria (below). The full text of the remaining articles was reviewed by two reviewers, with a third reviewer if a consensus was not reached by the first two reviewers. Eligibility was based on the following inclusion and exclusion criteria:

Inclusion criteria

We included studies that forecasted, predicted, or simulated any epidemiological or ecological phenomena about the Zika pandemic (including studies regarding previous outbreaks and epidemics, and regions outside the Americas), including but not limited to spatial spread risk, host and ecological range, disease and complication burden, economic impact transmission, and other epidemic dynamics. We didn’t require studies to explicitly present a future phenomenon risk, and we included time agnostic estimations of key epidemic parameters (for instance R0) and other phenomena. Did not include original analyses (e.g. review articles, perspective pieces, editorials, recommendations, and guidelines) Duplicated studies Animal and mosquito in-vivo pre-clinical models (e.g mouse, non-human primates) In vitro studies Descriptive epidemiological publications (e.g. describing case positive proportions, total case numbers, descriptive mapping of incidence by geographic information systems) positive proportions, total case numbers, descriptive mapping of incidence by geographic information systems) Models which only examined causality of ZIKV in Guillain-Barré Syndrome (GBS) or microcephaly (rather than estimating risk or burden, for example) Studies which only modeled non-ZIKV arboviruses, unless the central aim of the study was to explicitly forecast or predict ZIKV phenomena based on the known dynamics of other arboviruses

Data abstraction, collation, and analysis

Data were abstracted from the full texts by 12 reviewers (single-reviewer abstraction) across the domains of (i) objectives and study population, (ii) methodology and reproducibility, (iii) accessibility, timeliness, and other bibliometrics of eligible studies, and (iv) author affiliation and funding sources (S1 Table). In addition, the availability of preprint manuscripts was assessed using the pre-print search webtool search.bioPreprint [32], a server which identifies preprints from arXiv, bioRxiv, F1000Research, PeerJ Preprints, and Wellcome Open Research. Additionally, we manually searched arXiv and bioRxiv archives to confirm pre-print availability. These pre-print repositories are distinct from the advanced electronic publications made available by most journals after acceptance and peer review. Such ‘grey literature’ review extended beyond the cut-off date for the main literature database searches. A two-reviewer approach was used to ascertain whether eligible studies were made available as pre-print. From the abstracted data, descriptive analyses (medians, IQR, ranges, and proportions), and limited hypothesis testing were performed using Stata version 13.0 (StataCorp, College Station, TX, USA).

Results

Of 2034 studies identified, 73 articles published predominantly from 2016 to 2017 met the inclusion criteria (Fig 1) [20–26, 28, 33–97]. The most commonly predicted phenomena were spatial spread (34%), followed by R0 (basic reproductive number) or RE (effective reproductive number) (29%), epidemic dynamics (peak size/timing, final size and trajectory) (28%), microcephaly burden (15%), and vector competence and ecology (12%) (Table 1). While R0 and RE are not explicitly measurable (e.g. to validate an R0 prediction), studies estimating these values were also included due to their close relationship with predictions about epidemic dynamics [24, 37, 43, 47–49, 53–55, 58, 62, 66, 67, 76, 77, 80–82, 89, 91]. Most of the geographically resolved predictions were concentrated in the Americas (42%) and Asia-Pacific (21%), while few studies were from Africa (4%). Across 73 studies, the most commonly used data were infection case counts, vector data, and demographic data, followed by climate, meteorological, earth science, and transport data (Table 2). Vector data included any vector-related predictor or parameter data, including: spatial distributions and geographic ranges, seasonal/relative abundance, and vector trait data such as biting rate, virus competence, urban preference, endophily, salinity tolerance, extrinsic incubation period, mortality rate, lifespan, and habitat suitability [23, 26, 28, 33, 34, 38, 40–44, 47, 52, 53, 55–58, 67, 68, 71, 72, 84–86, 88, 90, 93, 95, 98]. Genomic data was not used in any of the studies and few studies used novel real-time internet data streams such as those harnessing open access social media and internet search engine platforms.
Fig 1

PRISMA flow-chart indicating the number of studies identified, screened, and confirmed for eligibility into this systematic review.

Table 1

Objectives and study population of eligible studies.

 n%a
Total number of studies73100
Zika-related phenomenon forecasted or predictedb
    Predicted microcephaly burdens1115
    Guillain-Barré syndrome burden34
    Epidemic peak size45
    Epidemic peak timing45
    Epidemic curve trajectory811
    Epidemic final size57
    Spatial spread2534
    Force of infection710
    Cost-effectiveness23
    Intervention impact34
    Case fatality ratio00
    Ro or REc2129
    Sexual transmission risk34
    Vector competence / ecology912
    Otherd23
Geographic region in which predictions madee
    Africa34
    Americas (excluding Continental USA)3142
    Asia–Pacific1521
    Continental USA710
    Europe45
    Global1824

aDenominator excludes those studies where unable or no basis to judge

bSome studies predicted more than one phenomenon

cIncluded estimates of R0

dEcological determinants of vector minimum abundance rate (n = 1); epidemic size and number of infections at time of first microcephaly case detected (n = 1)

eSome studies included >1 geographic category

Table 2

Data sources, methodology and reproducibility of eligible studies.

 N%a
Data types usedb  
    Case count4967
    Demographic2737
    Genomic sequence data00
    Climate, meteorological and earth science2129
    Transport1419
    Economic710
    Vector3041
    Internet search engine, social media or news-wire scraping data57
    Otherc912
Relevant data made available
    Entirely2940
    Partially2737
    Not at all1622
Model type(s) used in analysisd
    Stochastic2129
    Deterministic5676
Availability of statistical modeling computational code (e.g. R script provided)
    Entirely2129
    Partly710
    Not at all4562
Clear and accurate visual display of the model output
    Entirely4967
    Partly2027
    Not at all45
Estimates of prediction uncertainty provided (e.g. confidence intervals) provided
    Entirely3143
    Partly1318
    Not at all2839
Methods presented with a level of detail that allowed the study to be reproduced
    Entirely3754
    Partially2841
    Not at all46

aDenominator excludes those studies where unable or no basis to judge

bSome studies used multiple data types

cViremia duration and dynamics (n = 3); sexual contact network (n = 2); semen viral persistence (n = 2), non-human primate demographics (n = 1), mammalian diversity (n = 1)

dSome studies used both stochastic and deterministic models

aDenominator excludes those studies where unable or no basis to judge bSome studies predicted more than one phenomenon cIncluded estimates of R0 dEcological determinants of vector minimum abundance rate (n = 1); epidemic size and number of infections at time of first microcephaly case detected (n = 1) eSome studies included >1 geographic category aDenominator excludes those studies where unable or no basis to judge bSome studies used multiple data types cViremia duration and dynamics (n = 3); sexual contact network (n = 2); semen viral persistence (n = 2), non-human primate demographics (n = 1), mammalian diversity (n = 1) dSome studies used both stochastic and deterministic models Only 40% of studies made all relevant source data entirely accessible, while more than 20% of the eligible studies did not make any source data available either directly (e.g. an associated data repository) or indirectly (e.g. a citation or web-link) (Table 2). The visual display of model output was at least partly clear and accurate in 95% of the studies. Over a third of the studies did not present estimates of prediction uncertainty. Approximately half of the studies did not entirely present methods with a level of detail to allow reproducibility. Over 60% of the studies did not provide any computational code used for the analyses. We classified more models as deterministic (76%) as opposed to stochastic. It should be emphasized we only ultimately evaluated whether a model was deterministic versus stochastic. The large majority of published manuscripts were freely accessible (e.g. without a paywall), although 4% were published with paid access only (Table 3). Less than one third of manuscripts were posted on rapid preprint servers (e.g. bioRxiv) [99], prior to publication in a peer-reviewed journal. The median time from journal submission to e-journal publication was 93.5 days, with the maximum time greater than 1 year. This included delays after manuscript acceptance, 25% of the studies had delays of more than 24 days between acceptance and publication (Table 3). Most of the prediction studies were published late in the epidemic, well after the peaks in reported Zika cases (Fig 2, Fig 3). Submitting manuscripts to preprint servers made results available earlier by a median of 119 days (maximum 331 days, IQR 30–177 days) (Table 3). This shift led to more results being available close to the time of the 2016 South America and Central America epidemic peaks and prior to the epidemic peak in the Caribbean and the 2017 peak in Central America (Fig 2, Fig 3). Comparing the impact factor of journals accepting studies which were posted as preprints (versus the impact factor of those journals accepting studies which were not posted as pre-prints), there was no significant difference (median impact factor 4.37 vs. 4.45 respectively; p = 0.84 by Mann-Whitney U test).
Table 3

Accessibility, timeliness and other bibliometrics of eligible studies.

 n%d
Open accessa6896
Pre-print accessb2230
 medianIQR (range)
Journal impact factor4.372.65–7.62 (1.48–79.26)
Submission to acceptance time, days8344–112 (0–256)
Acceptance to publication time, daysc157–24 (-255–279)e
Submission to publication time, days93.547–141 (1–389)

aIncludes non-journal open access websites. Open access defined as able to be viewed without any payment or institutional journal license

bBiorxiv n = 19, ResearchGate n = 1, Bull WHO rapid journal pre-acceptance pre-print n = 2

cNegative values exist as Bull WHO articles published upon receipt (within 24 hrs) and then accepted later

dDenominator may vary in cases where these metrics were unable to be determined

ePublication time based on electronic journal version where available

Fig 2

Comparative trends of reported Zika cases in Latin American and publication times of Zika prediction studies.

Zika case counts were obtained from https://andersen-lab.com/ with permission.

Fig 3

Comparative trends in publication times of ZIKV prediction studies with and without the use of preprints.

Comparative trends of reported Zika cases in Latin American and publication times of Zika prediction studies.

Zika case counts were obtained from https://andersen-lab.com/ with permission. aIncludes non-journal open access websites. Open access defined as able to be viewed without any payment or institutional journal license bBiorxiv n = 19, ResearchGate n = 1, Bull WHO rapid journal pre-acceptance pre-print n = 2 cNegative values exist as Bull WHO articles published upon receipt (within 24 hrs) and then accepted later dDenominator may vary in cases where these metrics were unable to be determined ePublication time based on electronic journal version where available Over 90% of the studies included authors with academic affiliations (Table 4). Government affiliated authors participated in a minority of studies, although this may simply reflect “in-house” operational models not being published through journals. Among studies with identifiable funding sources, funding was divided among several sources, though the most common was the United States government, which funded or partially funded 50% of the studies (Table 4). However, many of those studies and others had a variety of funding sources, 85% had at least one non-U.S. government source. Non-governmental organizations were the second most common source, being included in 35% of the studies.
Table 4

Author affiliation and funding source of eligible studies.

Affiliation of authorsan%
    Academia6893
    Govt (US)1419
    Govt (non-US)1926
    Industryb45
    NGO1419
    Other type of organizationc45
Funding sourcedn%e
USG
    CDC12
    DHS24
    DoD36
    LANL12
    NASA12
    NIH2139
    NSA24
    NSF1222
    USAID12
    USDA36
    Other USGf12
    Any USG2750
Any Non-US Govt4685
Any Industry36
Any NGO1935
Any international normative body611
Otherg611

aMultiple affiliations associated with some studies

bScientific contracting/consulting (n = 3), spatial epidemiology software (n = 1)

cWorld Health Organization (n = 2), European Centers for Disease Control (n = 1), HealthMap (n = 1)

dMultiple funding streams associated with some studies

eUnable to be determined or unfunded in a number of studies, denominator = 54

fState Dept of Health (TX)

gAcademic intramural funding (n = 5)

aMultiple affiliations associated with some studies bScientific contracting/consulting (n = 3), spatial epidemiology software (n = 1) cWorld Health Organization (n = 2), European Centers for Disease Control (n = 1), HealthMap (n = 1) dMultiple funding streams associated with some studies eUnable to be determined or unfunded in a number of studies, denominator = 54 fState Dept of Health (TX) gAcademic intramural funding (n = 5)

Discussion

Public health agencies, policy-makers, and other stakeholders are carefully examining the response to Zika. Such ‘lessons-learned’ exercises have been fruitful for prior pandemics and outbreaks, including Ebola, SARS, MERS-CoV, pH1N1, and chikungunya viruses. These exercises have included introspection, analysis, and recommended action with respect to research, public health, and policy agendas [100-105]. To date, public health ‘lessons-learned’ activities related to the Zika PHEIC have focused on improved ethics preparedness for rapid research during public health emergencies [106], identification of other high-epidemic-risk pathogens with relatively inadequate countermeasure investment [107], expedited approaches to vaccine and other medical countermeasure development [108], rapid data-sharing and material transfer [109-111], and enhancing the role of media communication during epidemics [112]. In contrast to existing reviews on models developed during the ZIKV pandemic, which described specific contributions of modeling [113] or validated analytical assessment of results [114], this systematic review focused on capturing lessons that could improve the functional use of mathematical modeling in support of future infectious disease outbreaks. Extending an approach used by Chretien et al. in their evaluation of Ebola models, we focused on aspects of the studies that likely are particularly relevant to their usefulness during an outbreak [104]. This included modeling methods and input data, timeliness and accessibility of the publications, reproducibility (e.g. provision of data and code), and the communication of uncertainty. Our systematic review identified a large number of Zika models that predicted a wide range of epidemiological and ecological phenomena. The most commonly predicted phenomena were spatial spread, R0, epidemic dynamics, microcephaly burden, and vector competence. Notably few of the studies modeled the impact or cost-effectiveness of interventions, sexual transmission risk, or GBS burden. Not surprisingly, the majority of the studies were set in the Americas where most of the cases were reported during the pandemic. Notably one of the global gaps for understanding ZIKV dynamics is Africa, where ZIKV was discovered, is endemic, and poses a risk of future epidemics [115-117]. The leading data types for the examined studies were conventional case counts, vector, demographic, climate, and transport data. This finding reflects not only the availability but also the importance of such data. Case count data in particular are often hard to access but critical to many modeling approaches. Rapid sharing of case count data during international public health emergencies, as well as open, curated, rapidly accessible baseline demographic, human mobility, climate, and environmental datasets are essential to quickly leverage modeling and forecasting efforts [110]. Our review also identified several relatively underused data streams. First, socioeconomic and behavioral data were conspicuously absent. The lack of behavioral components in these models is concerning given the importance of these factors on disease dynamics [118]. Second, real-time internet-based data-streams, such as social media and internet search engine data, were used in a minority of ZIKV prediction studies identified in this systematic review. The limited use of internet ‘big data’ in the models suggests that either these data are of lower value for epidemic forecasting or that methods have yet to be developed to efficiently extract important information from them. Such data streams may be more commonly used in forecasting in the future as their strengths and weakness become clearer [119]. Genomic data were absent from these published models. During the pandemic, sequencing platforms were employed to generate data critical to diagnostic and countermeasure development [120], but our systematic review revealed that these data were not incorporated into prediction frameworks during the first year of ZIKV pandemic. This may reflect that early molecular epidemiology studies aimed to reconstruct the invasion and evolution of ZIKV rather than forecasting future changes [121, 122]. Some phylodynamic studies were published after the time period of the systematic review, with interesting results highlighting the possibility for phylogenetic data to provide unique insight into epidemic dynamics and possibly forecasting [122-124]. The relative delay of these studies (relative to those using other data sources) echoes a similar time lag of phylogenetic studies during the 2015 Ebola epidemic [104]. The lack of phylogenomic studies captured by this review also suggests that substantial bottlenecks still exist in using these data sources in epidemic response, despite advances in mobile near “real-time” sequencing technologies [120]. In the future, as new methods are developed, and genomic data become more readily available, the use of these data will likely become more common in prospective forecasting frameworks. Our systematic review did not delve deeply into modeling approaches, but did identify a preponderance of deterministic as opposed to stochastic models. Both categories of models have pros and cons and their use is often informed by the specific question being addressed, in addition to data availability [125]. Deterministic models may generally be easier to produce, but they may have limitations for intrinsically stochastic processes like epidemics, such as underestimating uncertainty, although deterministic models can also be implemented to estimate uncertainty [126]. Uncertainty is particularly important in this context where uncertainties are generated by the epidemic itself, data collection, and analytical approaches. Moreover, forecasts are ideally used to inform the mobilization of resources to save lives, a context in which clearly characterizing uncertainties is paramount. This is also a clear area for improvement in model output reporting; only 43% of studies entirely reported estimates of uncertainty. However, studies which did not present, say a credible interval around a forecasted phenomenon, may still have incorporated uncertainty in other ways which were not captured by the data abstraction tool, for instance a scenario analysis or incorporating uncertainty around parameters in a deterministic model. Our review also provided a unique evaluation of the more functional aspects of published predictions and forecasts. We determined that the visual clarity of model output was high but indicates room for improvement in publishing datasets used for model fitting and validation, and methodological detail to allow the study to be reproduced. Our results also identified the need for improved sharing of computational code to permit full result reproducibility. Shared model code could also be adapted by other researchers during time-sensitive epidemics. An important caveat here is that appropriate expertise and rigorous validation should be exercised before the use of model code developed by others, in the same fashion as other biomedical research fields which frequently disseminate code-based research tools in their publications (for instance, pathogen genomics and bioinformatics). The variable quality in sharing model code and methodological detail shown here does suggest that epidemic model reporting consensus guidelines, which establish a minimum standard for the reporting of epidemic modeling, may be valuable. A recent review of the modeling efforts for the Ebola epidemic also called for standardization of modeling practice [104]. Many other fields of biomedical research have established reporting guidelines to improve research quality and implementation [127-130]. While reporting guidelines have been proposed for population health modeling on a broader scale [131], none have been established for epidemics. This review also indicated that a majority of studies (60%) did not completely disclose the data they used. To the extent permissible with ethical and privacy constraints, publishing the aggregated data used to fit and validate models is critical. Not only would sharing data support full reproducibility, but sharing would also enable other researchers to use data in their own complementary modeling efforts. Modelers could therefore help answer calls for increased data sharing during public health emergencies [104, 110, 132]. Exploring how data can be shared more openly and quickly during a public health emergency would be useful, as this remains a challenge. Many studies identified in this review were published on a time-scale that was relevant to the Zika response. However, a large number of predictions were published well after the epidemic peaks, limiting their ability to inform the response. Nonetheless, those studies may well be used to inform other preparedness activities and contributed to the general knowledge of the biology, epidemiology and/or ecology of ZIKV. Further, results may have been informally shared with public health officials or other relevant decision makers prior to publication. Similar delays to publication have also been noted in an analysis of modeling efforts during the 2015 Ebola epidemic, which noted a median publication lag of around three months [103]. We identified two modifiable bottlenecks in the dissemination of results. First, delays from acceptance to journal publication were generally minimal (median 15 days), but a quarter of the evaluated studies had greater than 24 days delay from journal acceptance to publication. Immediate posting of accepted papers, as practiced by many journals, could cut this time down substantially. Second, we found that only 30% of studies were made available as preprints prior to peer review despite endorsements of preprints by major public agencies, funders, and journals. Those posted were available a median of 119 days prior to peer-reviewed publication. An analysis of preprints for all Zika publications over a similar time period found similar publication delays but much lower overall preprint use compared to the studies analyzed here (3.4% versus 30%) [133]. This greater adoption may indicate a changing preprint culture which was also reflected by our finding that preprint posting did not have a demonstrable effect on the impact factor of the journal in which the study was published, and we suggest that pre-prints be more frequently used in future public health emergencies, echoing other similar recent arguments [133]. Our review also provided a unique analysis of the funding sources and author affiliations of the published ZIKV prediction and forecast efforts across the ZIKV pandemic. These results indicated a range of stakeholders, and a diverse source of funding streams, including NGOs. We note that while academia contributed to the greatest volume of published studies, our search strategy would not have captured in-house models developed by US federal agencies or other unpublished models which may have provided direct operational support. Our data also suggested that the Government sector was the leading funder of all Zika prediction and forecasting studies during this period. Despite being a major stakeholder in ZIKV forecasts (e.g. prediction of whether it may have been feasible to plan a Phase III vaccine study in Latin America), we did not find evidence of pharmaceutical industry funded forecasting studies, although our search would not have identified unpublished models. This systematic review has three important weaknesses. First, due to scale, a completely independent two-reviewer system was not used for abstracting most of the data and for evaluation of aspects such as reproducibility. Second, we did not formally search for preprint manuscripts as part of the literature searching phase of the systematic review, only assessing whether eligible manuscripts had corresponding preprints. We may have therefore missed important research that had been posted but not yet peer-reviewed. Lastly, we had to restrict the time frame for publications to consider in the review. This restriction again led to missing studies, some of which may have already been published but not yet posted in EMBASE or MEDLINE. An additional challenge with our systematic review was that we did not provide a specific definition of “forecasting” and “prediction” to reviewers (to avoid an overly strict eligibility criteria). This led to collection of data on phenomena such as R0, which is an estimate as opposed to a forecast or prediction that could be potentially validated with data. Overall, the review identified several areas of improvement such as providing data and code, developing reporting standards, posting preprints, and communicating uncertainty. Addressing these areas can improve our understanding of Zika and other outbreaks and ensure that forecasts can inform preparedness and response to future outbreaks, epidemics, and pandemics.

PRISMA checklist.

(DOC) Click here for additional data file.

Data abstraction and study evaluation tool used by reviewers.

(DOCX) Click here for additional data file.
  120 in total

1.  Zika virus. I. Isolations and serological specificity.

Authors:  G W A DICK; S F KITCHEN; A J HADDOW
Journal:  Trans R Soc Trop Med Hyg       Date:  1952-09       Impact factor: 2.184

2.  Acute myelitis due to Zika virus infection.

Authors:  Sylvie Mécharles; Cécile Herrmann; Pascale Poullain; Tuan-Huy Tran; Nathalie Deschamps; Grégory Mathon; Anne Landais; Sébastien Breurec; Annie Lannuzel
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

3.  Low risk of a sexually-transmitted Zika virus outbreak.

Authors:  Laith Yakob; Adam Kucharski; Stephane Hue; W John Edmunds
Journal:  Lancet Infect Dis       Date:  2016-09-19       Impact factor: 25.071

4.  Estimate of the reproduction number of the 2015 Zika virus outbreak in Barranquilla, Colombia, and estimation of the relative role of sexual transmission.

Authors:  Sherry Towers; Fred Brauer; Carlos Castillo-Chavez; Andrew K I Falconar; Anuj Mubayi; Claudia M E Romero-Vivas
Journal:  Epidemics       Date:  2016-10-17       Impact factor: 4.396

5.  Zika Virus Associated with Microcephaly.

Authors:  Jernej Mlakar; Misa Korva; Nataša Tul; Mara Popović; Mateja Poljšak-Prijatelj; Jerica Mraz; Marko Kolenc; Katarina Resman Rus; Tina Vesnaver Vipotnik; Vesna Fabjan Vodušek; Alenka Vizjak; Jože Pižem; Miroslav Petrovec; Tatjana Avšič Županc
Journal:  N Engl J Med       Date:  2016-02-10       Impact factor: 91.245

6.  The Impact of Heterogeneity and Awareness in Modeling Epidemic Spreading on Multiplex Networks.

Authors:  Marialisa Scatà; Alessandro Di Stefano; Pietro Liò; Aurelio La Corte
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

7.  How Relevant Is Sexual Transmission of Zika Virus?

Authors:  Christian L Althaus; Nicola Low
Journal:  PLoS Med       Date:  2016-10-25       Impact factor: 11.069

8.  Mitigating Prenatal Zika Virus Infection in the Americas.

Authors:  Martial L Ndeffo-Mbah; Alyssa S Parpia; Alison P Galvani
Journal:  Ann Intern Med       Date:  2016-07-26       Impact factor: 25.391

9.  Utilizing Nontraditional Data Sources for Near Real-Time Estimation of Transmission Dynamics During the 2015-2016 Colombian Zika Virus Disease Outbreak.

Authors:  Maimuna S Majumder; Mauricio Santillana; Sumiko R Mekaru; Denise P McGinnis; Kamran Khan; John S Brownstein
Journal:  JMIR Public Health Surveill       Date:  2016-06-01

Review 10.  Internet-based biosurveillance methods for vector-borne diseases: Are they novel public health tools or just novelties?

Authors:  Simon Pollett; Benjamin M Althouse; Brett Forshey; George W Rutherford; Richard G Jarman
Journal:  PLoS Negl Trop Dis       Date:  2017-11-30
View more
  10 in total

Review 1.  Comparative overview of emerging RNA viruses: Epidemiology, pathogenesis, diagnosis and current treatment.

Authors:  Ishani Chakrabartty; Maryam Khan; Saurov Mahanta; Hitesh Chopra; Manish Dhawan; Om Prakash Choudhary; Shabana Bibi; Yugal Kishore Mohanta; Talha Bin Emran
Journal:  Ann Med Surg (Lond)       Date:  2022-06-11

2.  Spatio-Temporal Distribution of Aedes Albopictus and Culex Pipiens along an Urban-Natural Gradient in the Ventotene Island, Italy.

Authors:  Mattia Manica; Sara Riello; Carolina Scagnolari; Beniamino Caputo
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390

3.  A seq2seq model to forecast the COVID-19 cases, deaths and reproductive R numbers in US counties.

Authors:  Yanli Zhang-James; Jonathan Hess; Asif Salekin; Dongliang Wang; Samuel Chen; Peter Winkelstein; Christopher P Morley; Stephen V Faraone
Journal:  medRxiv       Date:  2021-04-20

Review 4.  A scoping review on research agendas to enhance prevention of epidemics and pandemics in Africa.

Authors:  Jill Ryan; Alison Wiyeh; Humphrey Karamagi; Joseph Okeibunor; Prosper Tumusiime; Charles Shey Wiysonge
Journal:  Pan Afr Med J       Date:  2020-11-24

5.  Recommended reporting items for epidemic forecasting and prediction research: The EPIFORGE 2020 guidelines.

Authors:  Simon Pollett; Michael A Johansson; Nicholas G Reich; David Brett-Major; Sara Y Del Valle; Srinivasan Venkatramanan; Rachel Lowe; Travis Porco; Irina Maljkovic Berry; Alina Deshpande; Moritz U G Kraemer; David L Blazes; Wirichada Pan-Ngum; Alessandro Vespigiani; Suzanne E Mate; Sheetal P Silal; Sasikiran Kandula; Rachel Sippy; Talia M Quandelacy; Jeffrey J Morgan; Jacob Ball; Lindsay C Morton; Benjamin M Althouse; Julie Pavlin; Wilbert van Panhuis; Steven Riley; Matthew Biggerstaff; Cecile Viboud; Oliver Brady; Caitlin Rivers
Journal:  PLoS Med       Date:  2021-10-19       Impact factor: 11.069

6.  Combining probabilistic forecasts of COVID-19 mortality in the United States.

Authors:  James W Taylor; Kathryn S Taylor
Journal:  Eur J Oper Res       Date:  2021-06-28       Impact factor: 6.363

Review 7.  The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be.

Authors:  Daniel Tusé; Somen Nandi; Karen A McDonald; Johannes Felix Buyel
Journal:  Front Plant Sci       Date:  2020-10-20       Impact factor: 5.753

Review 8.  Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases.

Authors:  Maria Lobato Gómez; Xin Huang; Derry Alvarez; Wenshu He; Can Baysal; Changfu Zhu; Victoria Armario-Najera; Amaya Blanco Perera; Pedro Cerda Bennasser; Andera Saba-Mayoral; Guillermo Sobrino-Mengual; Ashwin Vargheese; Rita Abranches; Isabel Alexandra Abreu; Shanmugaraj Balamurugan; Ralph Bock; Johannes F Buyel; Nicolau B da Cunha; Henry Daniell; Roland Faller; André Folgado; Iyappan Gowtham; Suvi T Häkkinen; Shashi Kumar; Sathish Kumar Ramalingam; Cristiano Lacorte; George P Lomonossoff; Ines M Luís; Julian K-C Ma; Karen A McDonald; Andre Murad; Somen Nandi; Barry O'Keefe; Kirsi-Marja Oksman-Caldentey; Subramanian Parthiban; Mathew J Paul; Daniel Ponndorf; Elibio Rech; Julio C M Rodrigues; Stephanie Ruf; Stefan Schillberg; Jennifer Schwestka; Priya S Shah; Rahul Singh; Eva Stoger; Richard M Twyman; Inchakalody P Varghese; Giovanni R Vianna; Gina Webster; Ruud H P Wilbers; Teresa Capell; Paul Christou
Journal:  Plant Biotechnol J       Date:  2021-07-19       Impact factor: 13.263

9.  Identification and evaluation of epidemic prediction and forecasting reporting guidelines: A systematic review and a call for action.

Authors:  Simon Pollett; Michael Johansson; Matthew Biggerstaff; Lindsay C Morton; Sara L Bazaco; David M Brett Major; Anna M Stewart-Ibarra; Julie A Pavlin; Suzanne Mate; Rachel Sippy; Laurie J Hartman; Nicholas G Reich; Irina Maljkovic Berry; Jean-Paul Chretien; Benjamin M Althouse; Diane Myer; Cecile Viboud; Caitlin Rivers
Journal:  Epidemics       Date:  2020-07-09       Impact factor: 4.396

10.  COVID-19 reopening strategies at the county level in the face of uncertainty: Multiple Models for Outbreak Decision Support.

Authors:  Katriona Shea; Rebecca K Borchering; William J M Probert; Emily Howerton; Tiffany L Bogich; Shouli Li; Willem G van Panhuis; Cecile Viboud; Ricardo Aguás; Artur Belov; Sanjana H Bhargava; Sean Cavany; Joshua C Chang; Cynthia Chen; Jinghui Chen; Shi Chen; YangQuan Chen; Lauren M Childs; Carson C Chow; Isabel Crooker; Sara Y Del Valle; Guido España; Geoffrey Fairchild; Richard C Gerkin; Timothy C Germann; Quanquan Gu; Xiangyang Guan; Lihong Guo; Gregory R Hart; Thomas J Hladish; Nathaniel Hupert; Daniel Janies; Cliff C Kerr; Daniel J Klein; Eili Klein; Gary Lin; Carrie Manore; Lauren Ancel Meyers; John Mittler; Kunpeng Mu; Rafael C Núñez; Rachel Oidtman; Remy Pasco; Ana Pastore Y Piontti; Rajib Paul; Carl A B Pearson; Dianela R Perdomo; T Alex Perkins; Kelly Pierce; Alexander N Pillai; Rosalyn Cherie Rael; Katherine Rosenfeld; Chrysm Watson Ross; Julie A Spencer; Arlin B Stoltzfus; Kok Ben Toh; Shashaank Vattikuti; Alessandro Vespignani; Lingxiao Wang; Lisa White; Pan Xu; Yupeng Yang; Osman N Yogurtcu; Weitong Zhang; Yanting Zhao; Difan Zou; Matthew Ferrari; David Pannell; Michael Tildesley; Jack Seifarth; Elyse Johnson; Matthew Biggerstaff; Michael Johansson; Rachel B Slayton; John Levander; Jeff Stazer; Jessica Salerno; Michael C Runge
Journal:  medRxiv       Date:  2020-11-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.